Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data
- PMID: 25155368
- DOI: 10.3111/13696998.2014.953680
Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data
Abstract
Purpose: This study aimed to explore the burden of illness associated with cervical dystonia (CD), including possible demographic and humanistic correlates of baseline disease severity.
Methods: The analysis involved the five multinational randomized, placebo-controlled clinical trials that had evaluated the efficacy and safety of Dysport® in patients with CD, including assessment using the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). Patient-level TWSTRS scores from the individual studies were meta-analysed to estimate disease severity at baseline. One of the studies had reported Short Form-36 (SF-36) Health Survey quality-of-life measures, and these data were used to investigate whether the severity of CD was associated with humanistic outcomes, as measured by health utility. A generalized regression model was then applied to explore potential correlation between TWSTRS scores and utilities.
Results: The estimated pooled mean baseline severity of CD in clinical trial entrants, as measured by TWSTRS score, was 43.23 (95% CI = 39.31-47.15). In general, disease severity was significantly greater in patients aged over 40 years (compared to the reference group aged 18-30 years). However, there was no correlation between disease severity and other demographic characteristics (e.g., weight, height, gender). Higher TWSTRS scores correlated with worse health-related quality of life as perceived by patients and was reflected in health utility (R(2 )= 0.133).
Conclusions: This study was able to define TWSTRS scores in patients with CD in terms of associated utility. This approach could help in capturing the disease's burden through measures that are more tangible than TWSTRS scores to patients, carers, clinicians, and healthcare payers.
Keywords: Burden of illness; Cervical dystonia; Meta-analysis; Patient-level data; TWSTRS; Utility.
Similar articles
-
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.Parkinsonism Relat Disord. 2010 Jun;16(5):316-23. doi: 10.1016/j.parkreldis.2010.03.002. Epub 2010 Mar 31. Parkinsonism Relat Disord. 2010. PMID: 20359934 Clinical Trial.
-
Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale.Parkinsonism Relat Disord. 2018 Jul;52:94-97. doi: 10.1016/j.parkreldis.2018.03.002. Epub 2018 Mar 7. Parkinsonism Relat Disord. 2018. PMID: 29530726 Clinical Trial.
-
The dystonia discomfort scale (DDS): a novel instrument to monitor the temporal profile of botulinum toxin therapy in cervical dystonia.Eur J Neurol. 2014 Mar;21(3):459-62. doi: 10.1111/ene.12330. Epub 2014 Jan 16. Eur J Neurol. 2014. PMID: 24433495 Clinical Trial.
-
Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.Drugs. 2002;62(4):705-22. doi: 10.2165/00003495-200262040-00011. Drugs. 2002. PMID: 11893235 Review.
-
A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia.J Neurol. 2016 Apr;263(4):772-80. doi: 10.1007/s00415-016-8050-2. Epub 2016 Feb 25. J Neurol. 2016. PMID: 26914922 Free PMC article.
Cited by
-
Sensorimotor Perceptive Rehabilitation Integrated (SPRInt) program: exercises with augmented movement feedback associated to botulinum neurotoxin in idiopathic cervical dystonia-an observational study.Neurol Sci. 2020 Jan;41(1):131-138. doi: 10.1007/s10072-019-04061-5. Epub 2019 Sep 2. Neurol Sci. 2020. PMID: 31478151 Clinical Trial.
-
Economic evaluation of AbobotulinumtoxinA vs OnabotulinumtoxinA in real-life clinical management of cervical dystonia.J Clin Mov Disord. 2020 Feb 11;7:2. doi: 10.1186/s40734-020-0083-0. eCollection 2020. J Clin Mov Disord. 2020. PMID: 32071728 Free PMC article.
-
Efficacy of Segmental Muscle Vibration on Pain Modulation in Patients with Primary Cervical Dystonia Treated with Botulinum Type-A Toxin: A Protocol for a Randomized Controlled Trial.NeuroSci. 2025 Apr 2;6(2):30. doi: 10.3390/neurosci6020030. NeuroSci. 2025. PMID: 40265360 Free PMC article.
-
Evaluation of anxiety and depression scales and quality of LIFE in cervical dystonia patients on botulinum toxin therapy and their relatives.Neurol Sci. 2019 Apr;40(4):725-731. doi: 10.1007/s10072-019-3719-9. Epub 2019 Jan 18. Neurol Sci. 2019. PMID: 30659417
-
Spectrum of practice in the routine management of cervical dystonia with abobotulinumtoxinA: findings from three prospective open-label observational studies.J Clin Mov Disord. 2018 Jul 9;5:4. doi: 10.1186/s40734-018-0072-8. eCollection 2018. J Clin Mov Disord. 2018. PMID: 30002865 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources